Corica Derek A, Bell Scott D, Zhao Lei, Lawler Nicholas J, Poirier McKade A, Miller Peyton J, Wakefield Mark R, Fang Yujiang
Department of Microbiology, Immunology & Pathology, Des Moines University, West Des Moines, IA 50266, USA.
The Department of Respiratory Medicine, the 2nd People's Hospital of Hefei and Hefei Hospital Affiliated to Anhui Medical University, Hefei 230002, China.
Cancers (Basel). 2025 May 31;17(11):1847. doi: 10.3390/cancers17111847.
Small cell lung cancer (SCLC) remains a challenge prognostically. A clinically silent early stage and predilection for early metastasis leads to over half of patients presenting with metastatic disease at the time of diagnosis. Akin to many other cancers, once SCLC metastasizes, current therapies begin to lose their effectiveness. The future of SCLC rests in innovative treatments aimed at improving patient outcomes. Chemotherapy and radiation remain the backbone treatment for SCLC. Most patients diagnosed with SCLC begin treatment with combination chemotherapy consisting of a platinum analog and topoisomerase inhibitor with or without concurrent radiation. Disease progression or recurrence warrants new treatment approaches. New chemotherapy combinations and advances in radiation precision offer patients novel approaches using the same backbone of treatment used in many other cancers. The introduction of newer therapeutic approaches, such as immune checkpoint inhibitors, small molecule targeted therapies, bispecific antibodies, and antibody-drug conjugates offer a bright future for patients with SCLC who fail first-line therapy. This review will focus on advancing treatment paradigms for SCLC in the era of precision medicine. Such a study might be helpful for pulmonologists and oncologists to manage precisely patients with SCLC.
小细胞肺癌（SCLC）在预后方面仍然是一个挑战。临床上无症状的早期阶段以及早期转移的倾向导致超过一半的患者在诊断时已出现转移性疾病。与许多其他癌症一样，一旦小细胞肺癌发生转移，目前的治疗方法就开始失去其有效性。小细胞肺癌的未来取决于旨在改善患者预后的创新治疗方法。化疗和放疗仍然是小细胞肺癌的主要治疗方法。大多数被诊断为小细胞肺癌的患者开始接受由铂类类似物和拓扑异构酶抑制剂组成的联合化疗，同时或不进行同步放疗。疾病进展或复发需要新的治疗方法。新的化疗组合以及放疗精准度的提高为患者提供了使用与许多其他癌症相同的主要治疗方法的新途径。更新的治疗方法的引入，如免疫检查点抑制剂、小分子靶向疗法、双特异性抗体和抗体药物偶联物，为一线治疗失败的小细胞肺癌患者带来了光明的未来。本综述将聚焦于精准医学时代小细胞肺癌治疗模式的进展。这样的研究可能有助于肺科医生和肿瘤学家精确管理小细胞肺癌患者。
